Glyxambi

AZ bounces back with diabetes combo win

After a late 2015 setback at the hands of the FDA, AstraZeneca is back with diabetes med Qtern—and ready to give rivals Lilly and BI some competition.

Carly Helfand Feb 28, 2017 11:33am

Fate of Lilly's Jardiance combo med rests on delayed FDA decision

Nov 1, 2016 1:32am